Evidence map›Paper›PMID 35628193›Full record

ArticleInternational journal of molecular sciences2022

Dichotomous Roles of

Yuanhua Lu, Jianan Zhao, Yafei Tian, Dan Shao, Zhiqi Zhang, Siqi Li, Jialin Li, Hugang Zhang, Wei Wang, Ping Jiao and 1 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. The injury effect of osteopontin in sepsis-associated lung injury.Journal of inflammation (London, England) · 2025
    Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yuanhua LuSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Jianan ZhaoSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Yafei TianSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Dan ShaoSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Zhiqi ZhangSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Siqi LiSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Jialin LiSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Hugang ZhangSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Wei WangSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Ping JiaoSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Jie MaSchool of Pharmaceutical Sciences, Jilin University, Changchun 130021, China.
Jilin University · CN

Funding

Department of Science and Technology of Jilin Province 20200403043SFJilin Province Development and Reform Commission 2022C014
6 · The paper itself

Abstract

Pulmonary fibrosis therapy is limited by the unclear mechanism of its pathogenesis. C57BL/6 mice were used to construct the pulmonary fibrosis model in this study. The results showed that

Indexed as

Multiple Endocrine Neoplasia Type 1Proto-Oncogene ProteinsPulmonary FibrosisAnimalsBleomycinFibroblastsMacrophagesMiceMice, Inbred C57BLBleomycinMen1 protein, mouseProto-Oncogene ProteinsmacrophageMen1OPNpulmonary fibrosispyroptosis

Identifiers

PMID35628193
PMCPMC9140697
OpenAlexW4280610535

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.